Over the projection period, the risk of onychomycosis in diabetic patients or the rising prevalence of diabetes worldwide are anticipated to fuel market expansion for onychomycosis treatments. For instance, diabetics are more likely than non-diabetics to develop onychomycosis, and they are also more likely to experience major consequences from the condition. The World Diabetes Federation estimates that 537 million individuals (20-79 years old), or one in ten, have diabetes as of the year 2021. By 2030 and 2045, this number is projected to increase to 643 million and 783 million, respectively. This could help the market for treating onychomycosis grow in turn. Throughout the forecast period, an increasing elderly population is anticipated to fuel market expansion for onychomycosis treatments.
The global Onychomycosis Treatment Market was valued at US$ 2,859.8 Mn in 2021 and is forecast to reach a value of US$ 4,185.4 Mn by 2028 at a CAGR of 5.7% between 2022 and 2028.
Key Companies in the Onychomycosis Treatment Industry:
Lumenis Ltd
Since 1966 Lumenis is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative
